Terumo Corporation (TRUMF)

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013	Mar 31, 2012
Americas Revenue	412.12B	395.65B	327.98B
Americas Revenue Growth	4.16%	20.63%	14.45%
Europe Revenue	226.53B	218.29B	191.50B
Europe Revenue Growth	3.77%	13.99%	19.67%
China Revenue	85.52B	84.97B	79.41B
China Revenue Growth	0.65%	7.00%	10.38%
Asia and Others Revenue	118.09B	120.05B	111.85B
Asia and Others Revenue Growth	-1.64%	7.34%	18.63%
Japan Revenue	220.16B	217.21B	211.12B
Japan Revenue Growth	1.36%	2.88%	1.80%

Revenue

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013	Mar 31, 2012
Cardiac and Vascular Company Revenue	640.15B	624.36B	555.72B
Cardiac and Vascular Company Revenue Growth	2.53%	12.35%	15.63%
Medical Care Solutions Company Revenue	212.60B	211.24B	197.57B
Medical Care Solutions Company Revenue Growth	0.64%	6.92%	3.03%
Blood and Cell Technologies Company Revenue	209.35B	200.28B	168.33B
Blood and Cell Technologies Company Revenue Growth	4.53%	18.98%	14.04%
Adjustments from Revenue	329.00M	298.00M	248.00M
Adjustments from Revenue Growth	10.40%	20.16%	2.06%

Adjusted EBIT

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013	Mar 31, 2012
Cardiac and Vascular Company Adjusted Operating Profit	164.82B	154.68B	123.85B
Cardiac and Vascular Company Adjusted Operating Profit Growth	6.56%	24.89%	10.43%
Medical Care Solutions Company Adjusted Operating Profit	23.78B	22.99B	19.79B
Medical Care Solutions Company Adjusted Operating Profit Growth	3.42%	16.19%	33.28%
Blood and Cell Technologies Company Adjusted Operating Profit	28.91B	26.48B	16.39B
Blood and Cell Technologies Company Adjusted Operating Profit Growth	9.17%	61.53%	46.86%
Adjustments from Adjusted Operating Profit	-3.65B	-712.00M	-3.25B

Key Performance Indicators

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013	Mar 31, 2012
Cardiac and Vascular Company Production Result	620.90B	576.61B
Cardiac and Vascular Company Production Result Growth	7.68%	12.91%
Medical Care Solutions Company Production Result	197.08B	192.89B
Medical Care Solutions Company Production Result Growth	2.17%	4.32%
Blood and Cell Technologies Company Production Result	205.67B	173.17B
Blood and Cell Technologies Company Production Result Growth	18.77%	7.15%
Total Production Result	1.02T	942.66B
Total Production Result Growth	8.59%	9.97%

Updated Sep 30, 2025. Data Source: Fiscal.ai.